T1D stands for Type 1 Diabetes, an autoimmune condition in which the body’s immune system attacks and destroys the cells in the pancreas that produce insulin. Without insulin, the body cannot move sugar from the bloodstream into cells for energy, causing blood sugar levels to rise dangerously high. An estimated 9.5 million people worldwide live with T1D, and roughly 513,000 new cases are diagnosed each year.
How T1D Develops
In a healthy body, clusters of cells in the pancreas called beta cells produce insulin whenever you eat. In T1D, specialized immune cells (T cells) mistakenly identify those beta cells as threats and destroy them. The attack involves direct cell-to-cell contact and the release of inflammatory chemicals that are toxic to beta cells. Those chemicals also recruit more immune cells to the pancreas, creating a feedback loop that accelerates the destruction.
By the time symptoms appear, a large portion of beta cell function has already been lost. This is why T1D can seem to come on suddenly even though the immune process may have been quietly building for months or years.
Common Symptoms and Warning Signs
The early symptoms of T1D reflect the body’s inability to use sugar properly. You may notice extreme thirst, frequent urination, unexplained weight loss, fatigue, and blurred vision. In children, bedwetting in a previously dry child is a common red flag.
If T1D goes unrecognized, it can progress to a dangerous complication called diabetic ketoacidosis (DKA). Without enough insulin, the body starts breaking down fat for fuel, producing acidic byproducts called ketones. DKA symptoms can escalate within 24 hours and include nausea, belly pain, fruity-scented breath, shortness of breath, and confusion. For some people, DKA is the very first sign that they have diabetes.
How T1D Differs From Type 2
The abbreviation “T2D” refers to Type 2 Diabetes, and the two conditions are fundamentally different despite sharing a name. T1D is driven by autoimmune destruction of beta cells, leaving the body unable to produce insulin at all. T2D is primarily a problem of insulin resistance: the body still makes insulin, but cells stop responding to it effectively. Over time, the pancreas may struggle to keep up with demand, but the underlying cause is different.
T2D is strongly linked to obesity, a sedentary lifestyle, and metabolic changes like abnormal cholesterol levels and chronic low-grade inflammation. T1D has no connection to weight or lifestyle. It can develop at any age, though it is most commonly diagnosed in children, teenagers, and young adults. A slower-onset form called LADA (Latent Autoimmune Diabetes in Adults) shares the same autoimmune mechanism but progresses more gradually, sometimes leading to an initial misdiagnosis of T2D. The key difference is that people with LADA test positive for autoantibodies against beta cells, while people with true T2D do not.
How T1D Is Diagnosed
Diabetes is diagnosed when blood sugar levels exceed specific thresholds. An A1C of 6.5% or higher, a fasting blood sugar of 126 mg/dL or higher, or a two-hour glucose tolerance test reading of 200 mg/dL or higher all indicate diabetes. A random blood sugar of 200 mg/dL or higher, combined with classic symptoms, can also confirm a diagnosis. These tests typically need to be repeated on a second day unless symptoms and results are clearly elevated.
To distinguish T1D from T2D, doctors look for autoantibodies in the blood, proteins that signal an immune attack on beta cells. The most commonly tested is GAD antibody. They also measure C-peptide, a molecule released alongside insulin. In T1D, C-peptide is very low or absent because the beta cells are destroyed. In T2D, C-peptide is normal or elevated because the pancreas is still producing insulin.
Living With T1D: Insulin and Technology
People with T1D need to replace the insulin their body can no longer make. This means either multiple daily injections or an insulin pump worn on the body. The goal is to mimic what a healthy pancreas does automatically: provide a steady background level of insulin throughout the day and deliver quick bursts at mealtimes.
Different types of insulin serve different roles. Rapid-acting insulin starts working within about 15 minutes, peaks at one hour, and lasts two to four hours, making it ideal for covering meals. Long-acting insulin takes about two hours to kick in, has no sharp peak, and provides steady coverage for up to 24 hours. Ultra-long-acting versions can last 36 hours or more. Most people with T1D use a combination of both.
Continuous glucose monitors (CGMs) have transformed daily management. These small sensors, worn just under the skin, track blood sugar levels every few minutes and send readings to a phone or receiver. Newer systems pair a CGM with an insulin pump to automatically adjust insulin delivery, reducing the number of manual decisions you need to make each day. The combination of these technologies helps keep blood sugar in a target range more consistently than injections and finger-stick testing alone.
A New Option for Delaying Onset
In 2022, the FDA approved the first drug capable of delaying the progression of T1D in people who are at high risk but haven’t yet developed full symptoms. In clinical trials, this treatment (a targeted antibody that calms the immune attack on beta cells) pushed back the onset of insulin-dependent T1D by a median of about two years compared to a placebo: 50 months versus 25 months. It is used in people aged 8 and older who have been identified through autoantibody screening as being in an early stage of the disease, before significant symptoms appear.
This doesn’t prevent T1D entirely, but gaining two additional years without the daily burden of insulin management is meaningful, especially for children and their families. It also signals a shift toward treating T1D as a condition that can be intercepted early rather than only managed after diagnosis.